How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

325,810 results for

cardio*

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. COVID-19 and Cardiovascular Disease Patients

in China median age 34-57 years across studies and 58% male prevalence of preexisting cardiovascular metabolic disease hypertension 17.1% (95% CI 9.9%-24%) in analysis of 4 studies with 1,415 patients cardiocerebrovascular disease 16.4% (95% CI 6.6%-26.1%) in analysis of 5 studies with 1,514 patients diabetes 9.7% (95% CI 6.9%-12.5%) in analysis of 5 studies with 1,514 patients PubMed 32161990 Clinical research in cardiology : official journal of the German Cardiac Society Clin Res Cardiol 20200311 (...) catheterization PubMed 32199938 Journal of the American College of Cardiology J Am Coll Cardiol 20200316 American College of Cardiology/Society of Cardiovascular Angiography and Intervention (ACC/SCAI) guidance on catheterization laboratory considerations during COVID-19 pandemic can be found in PubMed 32212409 Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions Catheter Cardiovasc Interv 20200325 Society of Cardiovascular Angiography

2020 DynaMed Plus

2. Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT Full Text available with Trip Pro

Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please (...) choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Enhanced motivational interviewing, in group or individual formats, did not reduce weight or increase physical activity in adults with high cardiovascular disease risk. {{author}} {{($index , , , , , , , , , , , , , , & . Khalida Ismail 1, * , Daniel Stahl 2 , Adam Bayley 1 , Katherine Twist 1 , Kurtis

2020 NIHR HTA programme

3. Implementation of interventions to reduce preventable hospital admissions for cardiovascular or respiratory conditions: an evidence map and realist synthesis Full Text available with Trip Pro

Implementation of interventions to reduce preventable hospital admissions for cardiovascular or respiratory conditions: an evidence map and realist synthesis Implementation of interventions to reduce preventable hospital admissions for cardiovascular or respiratory conditions: an evidence map and realist synthesis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found (...) . Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Factors facilitating implementation of interventions to reduce avoidable admissions for cardiovascular and respiratory conditions can be identified at a patient, general practitioner and health system level. {{author}} {{($index , & . Duncan Chambers * , Anna Cantrell, Andrew Booth School

2020 NIHR HTA programme

4. Promoting patient utilization of outpatient cardiac rehabilitation: ajoint International Council and Canadian Association of Cardiovascular Prevention and Rehabilitation position statement

Cardiovascular Health and Rehabilitation Association, Brazilian Association of Cardiorespiratory and Intensive Care Physiotherapy, Brazilian Group of Cardiopulmonary and Metabolic Rehabilitation, British Association for Cardiovascular Prevention and Rehabilitation, Canadian Association of Cardiovascular Prevention and Rehabilitation, Canadian Cardiovascular Society, Canadian Council of Cardiovascular Nurses, Cardiac Health Foundation of Canada, Cardiac Society Brunei Darussalam, Indonesian Heart Association (...) Promoting patient utilization of outpatient cardiac rehabilitation: ajoint International Council and Canadian Association of Cardiovascular Prevention and Rehabilitation position statement Promoting Patient Utilization of Outpatient Cardiac Rehabili... : Journal of Cardiopulmonary Rehabilitation and Prevention ')} You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Your account has been temporarily locked Your account has been

2020 CPG Infobase

5. Promoting patient utilization of outpatient cardiac rehabilitation: A joint International Council and Canadian Association of Cardiovascular Prevention and Rehabilitation position statement Full Text available with Trip Pro

them to complete programs. Previous article in issue Next article in issue Keywords Coronary artery disease Secondary prevention Health services accessibility Disease management Cardiac rehabilitation Recommended articles Citing articles (0) Endorsed by: American Society for Preventive Cardiology, Association Francophone de Cardiologie Préventive, Australian Cardiovascular Health and Rehabilitation Association, Brazilian Association of Cardiorespiratory and Intensive Care Physiotherapy, Brazilian (...) Group of Cardiopulmonary and Metabolic Rehabilitation, British Association for Cardiovascular Prevention and Rehabilitation, Canadian Association of Cardiovascular Prevention and Rehabilitation, Canadian Cardiovascular Society, Canadian Council of Cardiovascular Nurses, Cardiac Health Foundation of Canada, Cardiac Society Brunei Darussalam, Indonesian Heart Association, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Physical and Rehabilitation

2020 CPG Infobase

6. Ezetimibe for the prevention of cardiovascular Events

Ezetimibe for the prevention of cardiovascular Events 1 Translation of the executive summary of the rapid report A18-83 Ezetimib zur Prävention kardiovaskulärer Ereignisse (Version 2.0; Status: 3 September 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A18-83 Ezetimibe for the prevention of cardiovascular events 1 (...) Extract of rapid report A18-83 Version 2.0 Ezetimibe for the prevention of cardiovascular events 3 September 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ezetimibe for the prevention of cardiovascular events Commissioning agency: Federal Joint Committee Commission awarded on: 22 November 2018 Internal Commission No.: A18-83 Address of publisher: Institut für Qualität und

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

7. Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death

Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death Subcutaneous implantable cardio Subcutaneous implantable cardiov verter erter defibrillator insertion for pre defibrillator insertion for prev venting sudden enting sudden cardiac death cardiac death Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg603 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful (...) details about all patients having subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death onto a register by submitting data to the National Audit of Cardiac Rhythm Management database at the UK National Institute for Cardiovascular Outcomes Research (NICOR), and should review local clinical outcomes. 1.3 The procedure should only be done by clinicians with specific training on inserting the device. 2 2 Indications and current treatments Indications

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

8. Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death

Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death Published March 2020 Volume 20, Number 3 ONTARIO HEALTH TECHNOLOGY ASSESSMENT SERIES Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death: A Health Technology Assessment KEY MESSAGES What Is This Health Technology Assessment About? Heart failure is a condition in which the heart’s ability to pump enough blood to meet the body’s needs is reduced. Heart failure can occur (...) cardiocirculatory death (when the heart has stopped beating and there is no longer blood flow or a pulse). We looked at the budget impact of publicly funding this system for adult heart transplant recipients in Ontario. We also looked at the experiences, preferences, and values of people waiting for a heart transplant, people who had received a heart transplant, and family members of organ donors. What Did This Health Technology Assessment Find? Outcomes for people who received hearts donated after

2020 Health Quality Ontario

9. Cardiovascular disease prevention: applying All Our Health

Cardiovascular disease prevention: applying All Our Health Cardiovascular disease prevention: applying All Our Health - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Cardiovascular disease prevention: applying All Our Health Evidence and guidance to help healthcare (...) professionals to prevent heart attacks, strokes and dementia and to improve cardiovascular health. Published 9 January 2019 Last updated 16 December 2019 — From: Documents HTML Details This resource helps: front-line health professionals team leaders or managers senior or strategic leaders to prevent ill health and promote wellbeing as part of their everyday practice. We also recommend important actions that managers and staff holding strategic roles can take. View the full range of topics. Published 9

2020 Public Health England

10. Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications

Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Prescrire IN ENGLISH - Spotlight ''Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications'', 1 January 2020 {1} {1} {1} | | > > > Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight In the January issue of Prescrire International - Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications FREE DOWNLOAD In the "Reviews" section this month: what is dapagliflozin's harm-benefit balance in type 2 diabetes, in light of the results of a recent randomised, double-blind trial studying the drug's effect on cardiovascular outcomes? Full text available for free download. Summary A randomised, double-blind trial of dapagliflozin

2020 Prescrire

11. Cardiovascular Disease: Tailored Pharmacy-based Interventions to Improve Medication Adherence

Emirates" OR "U.S. Virgin Islands") #6 #1 AND #2 AND #3 AND #4 AND #5 LIMIT-TO ( LANGUAGE , "English" ) #7 TITLE-ABS-KEY("cardiovascular disease" or "coronary heart disease" or "ischemic" or "coronary artery disease" or "heart disease" or "heart attack" or "stroke" or "myocardial infarction" or "heart failure" or "cardiovascular disease” or "cerebrovascular disease" or "cerebrovascular event" or "angina" or "coronary disease" or "coronary artery disease" or "ischemia" OR cardiomyopathy OR “heart (...) Cardiovascular Disease: Tailored Pharmacy-based Interventions to Improve Medication Adherence Cardiovascular Disease: Medication Adherence | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) April 2019 Audience Adults Older Adults Setting Clinical/Health Systems Community Strategy Case Management

2020 Community Preventive Services Task Force

12. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Full Text available with Trip Pro

, as cardiologists, we are also concerned about whether patients with cardiovascular disease are at greater risk for 2019-nCoV, and whether new coronavirus infections have an impact on the cardiovascular system. Previous studies have shown a relationship between cardiovascular metabolic diseases and SARS and MERS [ , , ]. A systematic analysis of 637 MERS-CoV cases showed that diabetes and hypertension are prevalent in about 50% of the patients and cardiac diseases are present in 30% of the cases [ ]. Diabetes (...) of SARS-CoV, It can be speculated that 2019-ncov infection may affect the cardiovascular system through multiple mechanisms. First, viral infection directly causes damage to cardiomyocyte. According to Oudit’s study, SARS-CoV viral RNA was detected in 35% of autopsied human heart samples from SARS-CoV infected patients during the Toronto SARS outbreak [ ]. And they also confirmed that pulmonary infection with the human SARS-CoV in mice led to an ACE2-dependent myocardial infection [ ]. ACE2

2020 Covid-19 Ad hoc papers

13. COVID-19 and the cardiovascular system Full Text available with Trip Pro

COVID-19 and the cardiovascular system COVID-19 and the cardiovascular system | Nature Reviews Cardiology Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. A Nature Research Journal COVID-19 and the cardiovascular (...) , J. F. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395 , 514–523 (2020). 10. Sakabe, M., Yoshioka, R. & Fujiki, A. Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. J. Cardiol. Cases 8 , 173–175 (2013). Author information Affiliations Department of Cardiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

2020 Covid-19 Ad hoc papers

14. CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

the Chinese Medical Association (CMA). Sole responsibility of the translation rests with the Chinese Medical Association. This translation, Copyright ©2020 by the Chinese Medical Association (CMA). The original article entitled “Expert consensus on principal of clinical management of patients with severe emergent cardiovascular diseases during the epidemic period of COVID-19” [DOI: 10.3760/cma.j.cn112148-20200210-00066 Copyright ©2020] was prepared by (Yaling Han, MD, Department of Cardiology, General (...) Abstract In response to the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, the Chinese Society of Cardiology (CSC) issued this consensus statement after consulting with 125 medical experts in the fields of cardiovascular disease and infectious disease. The over-arching principles laid out here are the following: 1) Consider the prevention and control of COVID-19 transmission as the highest priority, including self-protection of medical staff; 2) Patient risk assessment of both

2020 Covid-19 Ad hoc guidelines

15. Covid-19: What is the evidence that cardiopulmonary resuscitation is aerosol generating?

adult patient group management-and- tracheal COVID-19 Critical Intelligence Unit 6 April 2020 References 1. Mahase E, Kmietowicz Z. Covid-19: Doctors are told not to perform CPR on patients in cardiac arrest. Bmj. 2020;368:m1282. 2. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020. 3. Fritz Z PG. Cardiopulmonary resuscitation after hospital admission with covid-19. BMJ 2020; 369 doi: https://doiorg/101136 (...) Covid-19: What is the evidence that cardiopulmonary resuscitation is aerosol generating? COVID-19 Critical Intelligence Unit 6 April 2020 Evidence check 6 April 2020 Cardiopulmonary resuscitation (CPR) Rapid review questions What is the evidence that cardiopulmonary resuscitation is aerosol generating? What is the current advice for CPR in patients with suspected or confirmed COVID-19? In brief ? There are case reports of transmission of different infectious diseases as a result

2020 Covid-19 Ad hoc papers

16. Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality

Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Prescrire IN ENGLISH - Spotlight '' Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality'', 1 May 2020 {1} {1} {1} | | > > > Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |    (...) |   |   |   |   |   |   |   |  Spotlight In the May issue of Prescrire International: Dulaglutide (Trulicity°) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality FREE DOWNLOAD In patients with type 2 diabetes who had a modest elevation of HbA1c, a recent trial suggested that addition of dulaglutide to hypoglycaemic therapy slightly reduced the risk of stroke, but did not reduce either all-cause mortality

2020 Prescrire

17. Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Societies Full Text available with Trip Pro

Journal of Cardiology. 2020; ( March 24th ) , Shah PB, Welt FGP, Mahmud E, et al. Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement. JACC Cardiovasc Interv. 2020. , Kirkpatrick J.N. Mitchell C. Taub C. Kort S. Hung J. Swaminathan M. ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak. J Am Coll Cardiol. 2020 (...) . J Am Coll Cardiol. 2020; Choi A.D. Abbara S. Branch K.R. et al. Society of Cardiovascular Computed Tomography Guidance for Use of Cardiac Computed Tomography Amidst the COVID-19 Pandemic. J Cardiovasc Comput Tomogr. 2020; ( Mar 21 (e-published ahead of print) ) : 2020 Haft J.W. Atluri P. Alawadi G. et al. Adult cardiac surgery during the COVID-19 Pandemic: A Tiered Patient Triage Guidance Statement. J Thorac Cardiovasc Surg. 2020 Apr 16; (e-published ahead of print) Hassan A. Arora R.C. Adams C

2020 Covid-19 Ad hoc guidelines

18. Tafamidis meglumine (Vyndaqel) - for the treatment of adult patients with cardiomyopathy due to transthyretin?mediated amyloidosis

Tafamidis meglumine (Vyndaqel) - for the treatment of adult patients with cardiomyopathy due to transthyretin?mediated amyloidosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product

2020 Health Canada - Drug and Health Product Register

19. Drug-induced heart valve disease: a blind spot for cardiologists

published in a specialised cardiology journal in 2014 (all quoted excerpts in this article are our translations), "before 2009, and even now", cardiologists have often mistaken the drug-induced heart valve disease they observed for rheumatic heart disease and, when surgery was performed, descriptions of excised valves referred to "presumed acute rheumatic fever" (5). For example, Marie-Christine Malergue, a cardiologist who has been a member of the expert panel on benfluorex for the French National (...) , trivialisation of the use of Mediator° while it was marketed, and alleged concealment of the drug's true nature, one of the charges brought against Servier (6,17). But other reasons relate specifically to the field of cardiology and cardiologists' education. Belated description of drug-induced heart valve disease in textbooks The author of the thesis states that, for about 40 years, cardiologists could not have learned to distinguish between rheumatic heart disease and drug-induced heart valve disease from

2020 Prescrire

20. A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study Full Text available with Trip Pro

A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry (...) , , , , , , , , , , & . Jessica M Harris 1 , Rachel C Brierley 1 , Maria Pufulete 1 , Chiara Bucciarelli-Ducci 2 , Elizabeth A Stokes 3 , John P Greenwood 4 , Stephen H Dorman 2 , Richard A Anderson 5 , Chris A Rogers 1 , Sarah Wordsworth 3 , Sunita Berry 6 , Barnaby C Reeves 1, * 1 Clinical Trials and Evaluation Unit, Bristol Trials Centre, University of Bristol, Bristol, UK 2 National Institute for Health Research (NIHR) Bristol Cardiovascular Research Unit, Bristol Heart Institute, University of Bristol, Bristol, UK 3

2019 NIHR HTA programme

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>